Inspection Record

Spectrum Laboratory Products — FDA 483 Findings

US FDAInspected 2023-03-24Published 2023-10-05 12 findingsQuality unit oversightCleaning validationValidation and qualificationDocumentation and recordsDeviation, CAPA, and investigationLaboratory and QC controlsOther quality systemComplaint and recall handlingStability and storageContamination control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The Quality Unit does not review and approve all appropriate quality-related documents.'' Specifically, a.

2Cleaning validation

Cleaning procedures are not validated.

3Validation and qualification

There is not an adequate number ofpersonnel qualified by appropriate training to perform and supervise the manufacture ofAPis.

4Documentation and records

02/08-02/10/23, 02/13, 02/15·02/17/23, 02/21-02/24/23,03/06,03/15,03/24/23 755,769 and 777 Jersey ~venue Batch Production and Control Records are not dated and signed when issued.

5Deviation, CAPA, and investigation

Written procedures are not established and followed for investigating critical deviations or the failure ofa batch of APT to meet specifications.

6Deviation, CAPA, and investigation

There is a failure to make sure that aJl critical deviations are investigated and resolved.

7Laboratory and QC controls

Laboratory control records do not include complete data derived from alJ tests conducted to ensure compliance with established specifications and standards, including examinations and assays.

8Documentation and records

Master Production Records do not include detailed production instructions.

9Other quality system

There is a lack ofdefined areas or other control systems for activities within the warehouse.

10Complaint and recall handling

There is a failure to conduct complaint investigations to determine the cause.

11Stability and storage

Failure to conduct stability studies to justify assigned expiration or retest dates ofrepackaged API products in different types ofcontainers/c1osures than that used by the API manufacturer.

12Contamination control

There is a failure to conduct repackaging operations under appropriate environmental conditions to avoid contamination and cross.contamination.

About this record

Extracted automatically from the document US FDA published on 2023-10-05. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Spectrum Laboratory Products company profile — full history US FDA documents, 2023 Go to Findings search